Drugs@FDA document
RINVOQ Letter · NDA 211675 SUPPL-22
Drugs@FDA document · ABBVIE · Apr 29, 2024
Key facts
| Drug name | RINVOQ |
|---|---|
| Document type | Letter |
| Application | NDA211675 |
| Submission | SUPPL-22 |
| Company | ABBVIE |
| Document date | Apr 29, 2024 |
At a glance
- Efficacy-New Patient Population Document categories
- 10–99 Documents for this application
- 1–9 USP chapters cited in this application's documents
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Drugs@FDA documents
Drugs@FDA posts the letters, labels, reviews and other documents behind each drug application and supplement. Orca1 indexes every document's full text and flags complete response letters.
Source: U.S. Food and Drug Administration (FDA), Drugs@FDA application documents · Source date: